section name header

Evidence summaries

Therapeutic Drug Monitoring of Antiretrovirals for People with HIV

There is not enough evidence to support routine use of therapeutic drug monitoring (TDM) of antiretrovirals (ARV) in ARV-naive or -experienced patients. TDM in treatment-naive participants on a protease inhibitor (PI)-based antiretroviral therapy regimen, particularly if unboosted by ritonavir, may improve virological outcomes. Level of evidence: "D"

A Cochrane review [Abstract] 1 included 8 studies with a total of 1 181 subjects. A meta-analysis including three studies did not show any significant effect on virological suppression below 500 HIV-RNA copies/mL at one year (RR 1.28, 95% Cl 0.86 to 1.92). Two trials including participants predominantly treated with unboosted PI-based regimens reported a 49% increased likelihood of achieving a HIV-RNA viral load below 500 copies/mL at 52 weeks (RR 1.49, 95% Cl 1.20 to 1.83). Safety outcomes were reported in four studies and were similar between TDM and standard of care. Uptake of expert advice based on TDM results was good in two trials (>70%), but low (<35%) in the remaining three studies that reported uptake of the recommendations.

References

  • Kredo T, Van der Walt JS, Siegfried N, Cohen K. Therapeutic drug monitoring of antiretrovirals for people with HIV. Cochrane Database Syst Rev 2009 Jul 8;(3):CD007268. [PubMed]

Primary/Secondary Keywords